Stifel Reiterates Buy Rating on Olema Pharmaceuticals (OLMA): Roche Ph3 outcome "not optimal for OLMA stock near term"

March 9, 2026 8:41 AM

Stifel analyst Laura Prendergast reiterated a Buy rating and $48.00 price target on Olema Pharmaceuticals (NASDAQ: OLMA)The analyst commented, "This ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found